Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
477.37
+5.37 (+1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
51
52
Next >
Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial
December 13, 2023
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage
Via
Benzinga
Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment
December 13, 2023
The company tested an alternative to opioids and NSAIDs in patients with diabetic peripheral neuropathy.
Via
Investor's Business Daily
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
December 13, 2023
The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks.
Via
InvestorPlace
Exposures
COVID-19
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading
December 13, 2023
Via
Investor Brand Network
1 Biotech Stock That Could Be the Next Amgen
December 13, 2023
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.
Via
The Motley Fool
Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative
December 13, 2023
Vertex stock spiked early Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.
Via
Investor's Business Daily
The Latest Analyst Ratings for Vertex Pharmaceuticals
December 11, 2023
Via
Benzinga
Forget the "Magnificent Seven": Buy This Stock Instead
December 09, 2023
It's hard to go wrong with this high-flying drugmaker.
Via
The Motley Fool
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
December 13, 2023
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.
Via
The Motley Fool
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
December 13, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
December 12, 2023
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology.
Via
Investor's Business Daily
Exposures
Product Safety
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Why CRISPR Stock Keeps Falling
December 11, 2023
CRISPR just scored its first FDA victory -- but profits remain years away.
Via
The Motley Fool
Exposures
Product Safety
Bull Of The Day: Crispr Therapeutics
December 11, 2023
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...
Via
Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
December 11, 2023
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Right Now
December 10, 2023
These stocks could be just the ticket for investors seeking strong growth.
Via
The Motley Fool
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
December 10, 2023
The big biotech's shares have been on the rise this year.
Via
The Motley Fool
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
December 09, 2023
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.
Via
The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 08, 2023
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y
Via
Benzinga
Exposures
Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
December 08, 2023
Treasury yields and crude oil came off multimonth lows on Friday's jobs report.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment
December 08, 2023
Crispr stock rose in early trades on Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment.
Via
Investor's Business Daily
Exposures
Product Safety
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
December 08, 2023
The timing of the cuts is setting off alarm bells, but the situation is under control.
Via
The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
December 07, 2023
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks.
Via
InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
December 07, 2023
Shareholders will do well to prepare themselves for how regulators might react.
Via
The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
December 07, 2023
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.
Via
The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
Vertex Appoints Nancy Thornberry to its Board of Directors
December 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.